Dabigatran etexilate mesylate, better known as Pradaxa, is manufactured by Boehringer Ingelheim Pharmaceuticals (BI) and gained approval from the US Food and Drug Administration (FDA) in October 2010. Within the first three-months of its introduction to the US market, the anticoagulant, blood thinning, drug had been given to roughly 86,000 patients by retail pharmacies. Because it is classified as a Direct Thrombin Inhibitor, or blood thinner, Pradaxa is prescribed to decrease the risk of blood clots and stroke in individuals (read more)
Read More
23
Mar
2012
What is Pradaxa and What Does it Do?
22
Mar
2012
Do You Have a Pradaxa Lawsuit?
The safety of the blood thinning medication Pradaxa has recently come into question as many experts have linked it to increasing patients’ risk for life threatening bleeding. In the first quarter of 2011 alone, the US Food and Drug Administration (FDA) received more than 500 reports of bleeding problems related to Predaxa, just months after the drug had been released into the market. In a quarterly drug safety report, the Institute of Safe Medication Practices (ISMP), which records all severe, (read more)
Read More